Zhitong Hong Kong Stocks Early Insights | Two Giants Announce Rare Earth Price Increases! Nasdaq and S&P 500 Indexes Both Reach All-Time Highs During Trading

【Today's Headlines】

Two Giants Announce: Rare Earth Price Increase!

On the evening of July 10, Northern Rare Earth and Baogang Co., Ltd. both announced plans to adjust the related transaction price of rare earth concentrates for the third quarter of 2025 to RMB 19,109 per ton (excluding tax, dry weight, REO=50%, same below). For every 1% increase or decrease in REO, the price will increase or decrease by RMB 382.18 per ton.

Guotou Securities released an industry research report stating that a rise in rare earth prices is expected. The report pointed out that on April 4, 2025, the export control on medium and heavy rare earths was implemented, restricting the export of seven items including dysprosium and terbium, which triggered panic in overseas supply chains. The prices of dysprosium and terbium in Europe skyrocketed, with domestic and foreign price differences exceeding three times. As magnet material companies gradually obtained export licenses in May, exports began to recover, and the price of praseodymium and neodymium oxide rose moderately. Currently, the industry chain is waiting for quota implementation, and it is expected that the overall quota for rare earths in 2025 will slow down year-on-year growth. On the demand side, the demand for new energy vehicles, wind power, and home appliances continues to grow rapidly, and it is expected that humanoid robots will enter mass production in the short term, quickly becoming an important application field for high-performance neodymium-iron-boron. Leading magnet material companies have begun to supply orders. With the continuous growth in demand, the supply and demand of praseodymium and neodymium may improve. The report predicts that a demand gap will appear in the global praseodymium and neodymium oxide market, and prices are expected to continue rising. As exports gradually recover, the price difference between domestic and foreign medium and heavy rare earths is expected to converge, and there is optimism about the price increase of domestic dysprosium oxide and terbium oxide. The Hong Kong stock related to the rare earth concept is Jinli Permanent Magnet (06680).

【Market Outlook】

Overnight U.S. Stocks All Rise, Nasdaq and S&P 500 Indexes Hit All-Time Highs During Trading

Overnight, U.S. stocks closed with the Dow Jones Industrial Average up 192.34 points, an increase of 0.43%, closing at 44,650.64 points; the Nasdaq rose 19.33 points, an increase of 0.09%, closing at 20,630.66 points; the S&P 500 index rose 17.20 points, an increase of 0.27%, closing at 6,280.46 points. Both the Nasdaq and S&P 500 indexes hit all-time highs during trading. Tesla (TSLA.US) rose 4.7%, Nvidia (NVDA.US) rose nearly 1%, with a closing market value of $4 trillion. The Nasdaq Golden Dragon China Index rose 0.9%, and ZTO Express (ZTO.US) rose 9%. The Hang Seng Index ADR rose, closing at 24,122.28 points, an increase of 93.91 points or 0.39% compared to the Hong Kong close.

【Hot Topics Ahead】

Countdown to 50% Copper Tariff in the U.S. Global Copper Traders Accelerate Resale of Inventory to China

According to Zhitong Finance APP, global copper traders are offering copper products to Chinese buyers as they hope to process copper inventory that cannot be shipped to the U.S. before the 50% copper tariff deadline set by President Trump. Trump stated later on Wednesday that this new tariff will take effect on August 1, aimed at promoting domestic production of various products from semiconductors to ammunition. However, he did not specify which copper products would be affected or whether exceptions would be considered.

Fast Retailing (06288) Announces Third Quarter Results, Parent Company's Profit Attributable to Owners Reaches 339.099 Billion Yen, Up 8.4% Year-on-Year According to the Zhitong Finance APP, Fast Retailing (06288) announced its nine-month performance ending May 31, 2025, with revenue of 2,616.708 billion yen, a year-on-year increase of 10.6%; profit attributable to the parent company was 339.099 billion yen, a year-on-year increase of 8.4%; basic earnings per share were 1,105.36 yen.

Ant International denies cooperation with Circle

Recently, there were reports that Ant International was collaborating with Circle. Ant International stated that the media reports were inaccurate and that there are currently no such plans.

China Biologic Pharmaceutical (01177): Application for new indication of Kumosiri capsules for first-line treatment of breast cancer accepted

According to the Zhitong Finance APP, China Biologic Pharmaceutical (01177) announced that its self-developed CDK2/4/6 inhibitor Kumosiri capsules "TQB3616" combined with Fluvestrant injection for previously untreated HR-positive, HER2-negative (HR+/HER2-) locally advanced or metastatic breast cancer has submitted a new indication application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China and has been accepted.

Yue Yuen Industrial (00551) reports approximately $4.06 billion in net operating income for the first half of the year, a year-on-year increase of 1.1%

According to the Zhitong Finance APP, Yue Yuen Industrial (00551) announced that for June 2025, the company's net operating income was approximately $657 million, an increase of 1.5% year-on-year. The cumulative net operating income for January to June was approximately $4.06 billion, a year-on-year increase of 1.1%.

Hui Ju Technology (01729) issues profit warning, expects mid-term net profit to grow by about 50% to 60%

According to the Zhitong Finance APP, Hui Ju Technology (01729) announced that it expects the group's net profit for the six months ending June 30, 2025, to increase by approximately 50% to 60% compared to the net profit disclosed in its mid-term report for the six months ending June 30, 2024.

Qiu Tai Technology (01478) issues profit warning, expects mid-term comprehensive profit to increase by about 150%-180% year-on-year

According to the Zhitong Finance APP, Qiu Tai Technology (01478) announced that it expects the group's comprehensive profit for the six months ending June 30, 2025, to increase by approximately 150%-180% compared to the comprehensive profit of approximately RMB 115 million for the six months ending June 30, 2024.

BeiGene (06160): European Commission approves Baizean in combination with chemotherapy for first-line treatment of nasopharyngeal carcinoma patients

On July 10, BeiGene announced that the European Commission has approved Baizean® in combination with Gemcitabine and Cisplatin for first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma who are not suitable for radical surgery or radiotherapy China Lilang (01234): Retail sales of "LILANZ" products achieved mid to high single-digit growth year-on-year in the first half of the year

According to the Zhitong Finance APP, China Lilang (01234) announced that the retail sales amount of "LILANZ" products (calculated at retail value) achieved mid to high single-digit growth compared to the same period in 2024 in the second quarter of 2025.

Bank of China Aviation Leasing (02588) sold a total of 18 aircraft in the first half of the year

According to the Zhitong Finance APP, Bank of China Aviation Leasing (02588) announced its operational trading situation for the second quarter ending June 30, 2025. The portfolio includes a total of 834 owned, managed, and ordered aircraft and engines, with an average age of 5.0 years for the 441 owned aircraft and an average remaining lease term of 7.9 years. The managed fleet includes 32 aircraft, and the order book includes 351 aircraft. The customer base for the owned and managed fleet covers 92 airlines in 45 countries and regions, with a utilization rate of 100% for owned aircraft in the second quarter.

WuXi AppTec (02359) issues profit warning, expects net profit attributable to the parent company of approximately RMB 8.561 billion, a year-on-year increase of approximately 101.92% in the first half of the year

According to the Zhitong Finance APP, WuXi AppTec (02359) announced that the company expects to achieve operating revenue of approximately RMB 20.799 billion in the first half of 2025, a year-on-year increase of approximately 20.64%, with revenue from continuing operations increasing by approximately 24.24% year-on-year. The adjusted net profit attributable to the parent company is expected to be approximately RMB 6.315 billion, a year-on-year increase of approximately 44.43%. The net profit attributable to the shareholders of the company, excluding non-recurring gains and losses, is expected to be approximately RMB 5.582 billion, a year-on-year increase of approximately 26.47%. The net profit attributable to the shareholders of the company is expected to be approximately RMB 8.561 billion, a year-on-year increase of approximately 101.92%; the total profit for the period is expected to be approximately RMB 9.907 billion, a year-on-year increase of approximately 96.20%; the basic earnings per share for the period is expected to be approximately RMB 3.01 per share, a year-on-year increase of approximately 106.16%.

Singularity Guofeng (01280) plans to acquire an AI technology service company focused on interest e-commerce AI empowerment services

Singularity Guofeng (01280) announced that the company signed a non-binding investment intention letter with the seller on July 10, 2025, intending to acquire 100% equity of an AI technology company focused on interest e-commerce AI empowerment services. The target company's valuation range is between HKD 350 million and HKD 500 million, and the final consideration will be determined based on the valuation report issued by an independent appraisal agency and the results of the company's legal and financial due diligence. The consideration for the potential transaction is intended to be paid in shares issued by the company listed on the Hong Kong Stock Exchange. The company will conduct due diligence on the target group within two months from the signing of the investment intention letter and will further negotiate with the seller to sign a formal and binding agreement regarding the potential acquisition within two months from the signing date GAC HUAWEI has planned two new vehicles, expected to be released next year

GAC Group, in collaboration with Huawei, has planned two models for HUAWEI Automotive, one sedan and one SUV, with power options including pure electric and range-extended, expected to debut next year. The style of the two new vehicles is close to the currently hottest brands in the market above 200,000, but the positioning may be more high-end. GAC has previously disclosed that HUAWEI primarily targets the 300,000-level market. In response to the above information, we have sought verification from HUAWEI Automotive, which replied that it will adhere to the previously released official information. This involves the Hong Kong stock GAC Group (02238).

Dongyue Group (00189) issues profit warning, expects a significant year-on-year increase of approximately 150% in net profit attributable to shareholders for the first half of the year

According to Zhitong Finance APP, Dongyue Group (00189) announced that it expects the net profit attributable to shareholders for the year ending June 30, 2025, to increase significantly by approximately 150% year-on-year. Based on existing information, the board believes that the main reason for the above growth is the significant increase in the prices of certain refrigerant products compared to the same period last year.

Guokao Group (00053): Rank Group's annual like-for-like net gaming revenue increased by 11%, reaching approximately £795 million

According to Zhitong Finance APP, Guokao Group (00053) announced the business performance of its subsidiary The Rank Group Plc for the twelve months ending June 30, 2025. Rank Group's annual like-for-like net gaming revenue increased by 11%, reaching approximately £795 million. Rank Group currently expects its annual like-for-like operating profit to be at least £63 million.

【Stock Highlights】

Ascentage Pharma -B (06855): New Bcl-2 inhibitor Lisatoclax officially approved by the National Medical Products Administration of China for the treatment of adult chronic lymphocytic leukemia / small lymphocytic lymphoma patients

According to Zhitong Finance APP, Ascentage Pharma -B (06855) announced that its independently developed new Bcl-2 selective inhibitor Lisatoclax® (generic name: Lisatoclax; development code: APG-2575) has been conditionally approved for marketing by the National Medical Products Administration (NMPA) of China for adult chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patients who have previously undergone at least one systemic treatment including Bruton’s tyrosine kinase (BTK) inhibitors. This means that the domestically developed Lisatoclax® becomes the first Bcl-2 inhibitor approved in China for the treatment of CLL/SLL and the second Bcl-2 inhibitor approved globally